{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:26:08Z","timestamp":1768559168036,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010733","name":"Danish Childhood Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chugai Pharmaceutical Co., Ltd."},{"name":"Kyowa Hakko Kirin Co., Ltd."},{"name":"Nippon Kayaku Co., Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.critrevonc.2020.102939","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T05:34:46Z","timestamp":1585978486000},"page":"102939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-0323","authenticated-orcid":false,"given":"Astrid","family":"Eliasen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Dalhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Mathiasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Rechnitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid Blicher","family":"Schelde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dyah Aryani","family":"Perwitasari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Brok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.102939_bib0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000087979","article-title":"5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment","volume":"69","author":"Aapro","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clpt.2005.08.015","article-title":"Association of the ABCB1 3435C&T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists","volume":"78","author":"Babaoglu","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpt.598","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron","volume":"102","author":"Bell","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00000542-200503000-00011","article-title":"The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?","volume":"102","author":"Candiotti","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0030","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0090-9556(25)06820-5","article-title":"Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans","volume":"23","author":"Dixon","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0035","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00432-008-0387-1","article-title":"Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy","volume":"134","author":"Fasching","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0040","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3109\/00365521.2015.1132336","article-title":"The impact of genetic factors on response to glucocorticoids therapy in IBD","volume":"51","author":"Gabryel","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0050","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/pgs.10.67","article-title":"Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy","volume":"11","author":"Hammer","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0055","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.clinthera.2014.06.016","article-title":"Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting","volume":"36","author":"He","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0060","first-page":"277","article-title":"2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy","volume":"25","author":"Herrstedt","year":"2017","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0065","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0070","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0075","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1200\/JCO.1998.16.9.2937","article-title":"Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis","volume":"16","author":"Italian Group for Antiemetic Research","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00008571-200405000-00001","article-title":"Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists","volume":"14","author":"Kaiser","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0085","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1200\/JCO.2002.09.064","article-title":"Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes","volume":"20","author":"Kaiser","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/ajco.12575","article-title":"Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients","volume":"13","author":"Kang","year":"2017","journal-title":"Asia. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0095","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1188\/16.ONF.389-393","article-title":"Genetic influence on chemotherapy-induced nausea and vomiting: a narrative review","volume":"43","author":"Kiernan","year":"2016","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00228-003-0595-1","article-title":"Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects","volume":"59","author":"Kim","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0105","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/523601","article-title":"A randomized, double-blind pilot study of dose comparison of ramosetron to prevent chemotherapy-induced nausea and vomiting","volume":"2015","author":"Kim","year":"2015","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0110","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.suronc.2017.09.004","article-title":"ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: a meta-analysis","volume":"26","author":"Madrid-Paredes","year":"2017","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0120","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1248\/bpb.b16-00440","article-title":"An analysis of behavioral and genetic risk factors for chemotherapy-induced nausea and vomiting in Japanese subjects","volume":"39","author":"Mukoyama","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1067\/mcp.2002.122055","article-title":"Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects","volume":"71","author":"Nakamura","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0130","series-title":"NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 2.2019","author":"National Comprehensive Cancer Network (NCCN)","year":"2019"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/mol.106.032144","article-title":"Characterization of the novel human serotonin receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E","volume":"72","author":"Niesler","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0140","first-page":"1","article-title":"Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer","volume":"2","author":"Oliva","year":"2017","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/IGC.0b013e318234f9ee","article-title":"Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer","volume":"22","author":"Perwitasari","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11096-010-9454-1","article-title":"Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics","volume":"33","author":"Perwitasari","year":"2011","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0155","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/jjco\/hyr117","article-title":"Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy","volume":"41","author":"Perwitasari","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0160","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/acschemneuro.6b00132","article-title":"Palonosetron-5-HT3 receptor interactions as shown by a binding protein cocrystal structure","volume":"7","author":"Price","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-014-2832-y","article-title":"Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer","volume":"144","author":"Pud","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.102939_bib0170","first-page":"2911","article-title":"Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors","volume":"26","author":"Puri","year":"2018","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00003088-199529020-00004","article-title":"Ondansetron clinical pharmacokinetics","volume":"29","author":"Roila","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0180","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1023\/A:1012244520615","article-title":"MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects","volume":"18","author":"Sakaeda","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0185","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2017.11.012","article-title":"A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting","volume":"121","author":"Singh","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2020.102939_bib0195","article-title":"Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta\u2010analysis","volume":"2017","author":"Skoetz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1213\/ANE.0b013e31821d01bc","article-title":"CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care","volume":"113","author":"Stamer","year":"2011","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/pgs.14.168","article-title":"Pharmacogenetics of chemotherapy-induced nausea and vomiting","volume":"16","author":"Sugino","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0210","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0215","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11912-013-0312-x","article-title":"Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?","volume":"15","author":"Trammel","year":"2013","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0220","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO.2003.05.164","article-title":"Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients","volume":"21","author":"Tremblay","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0225","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2133\/dmpk.DMPK-12-RG-084","article-title":"Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients","volume":"28","author":"Tsuji","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.102939_bib0230","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/tpj.2016.38","article-title":"Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study","volume":"17","author":"Tsuji","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0235","first-page":"1057","article-title":"Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial","volume":"20","author":"Tsuji","year":"2012","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/tpj.2010.75","article-title":"Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron","volume":"12","author":"Tzvetkov","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0245","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C&T affects mRNA stability","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0250","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2217\/14622416.9.8.1027","article-title":"Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy","volume":"9","author":"Ward","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0255","author":"Wells"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0260","first-page":"1505","article-title":"Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy","volume":"26","author":"Yokoi","year":"2018","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0265","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.clbc.2017.05.013","article-title":"Genetic risk factors associated with antiemetic efficacy of Palonosetron, aprepitant, and dexamethasone in Japanese breast cancer patients treated with anthracycline-based chemotherapy","volume":"18","author":"Yokoyama","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2020.102939_bib0270","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/jcmm.12751","article-title":"Genetic model","volume":"20","author":"Zhao","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.critrevonc.2020.102939_bib0275","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/bcpt.12334","article-title":"Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter","volume":"116","author":"Zoto","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820300779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820300779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:31:43Z","timestamp":1760902303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820300779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":55,"alternative-id":["S1040842820300779"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102939","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102939"}}